Inactive Instrument

Shilpa Medicare Ltd Stock NSE India S.E.

Equities

INE790G01023

Pharmaceuticals

End-of-day quote NSE India S.E.
- INR - Intraday chart for Shilpa Medicare Ltd
Sales 2022 11.47B 137M Sales 2023 10.52B 126M Capitalization 19.91B 238M
Net income 2022 607M 7.27M Net income 2023 -325M -3.89M EV / Sales 2022 3.58 x
Net Debt 2022 6.58B 78.77M Net Debt 2023 7.79B 93.27M EV / Sales 2023 2.63 x
P/E ratio 2022
54.7 x
P/E ratio 2023
-61.3 x
Employees -
Yield 2022
0.28%
Yield 2023
-
Free-Float 40.56%
More Fundamentals * Assessed data
Shilpa Medicare Arm's API Facility in Karnataka, India, Passes Brazilian Drug Regulator's Inspection MT
Shilpa Medicare to Receive Shares from Unit as Loan Payment MT
Transcript : Shilpa Medicare Limited - Shareholder/Analyst Call
Shilpa Medicare Shares Rally 16% as Client Reports Positive Clinical Trial Results MT
INDIA STOCKS-HDFC Bank drags Indian shares as rally to record highs takes pause RE
Unicycive Therapeutics, Inc. Enters into First Amendment to Manufacturing and Supply Agreement with Shilpa Medicare, Ltd CI
Shilpa Medicare Bio Analytical Unit Gets "No Action Indicated" Classification from US FDA MT
Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024
Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Shilpa Medicare Limited Announces Successful Completion of Early Clinical Development and Ongoing Phase 3 Clinical Trial of Its Newly Developed Drug "SML-007", for the Treatment of Non-Alalcoholic Fatty Liver Disease CI
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US MT
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit MT
Shilpa Medicare Gets Board Nod to Launch QIP MT
Shilpa Medicare's Life Science Arm Names CEO MT
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA MT
More news

Latest transcript on Shilpa Medicare Ltd

Managers TitleAgeSince
Chief Executive Officer 63 87-11-19
Director of Finance/CFO - 21-05-30
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 63 87-11-19
Director/Board Member 59 21-09-01
Director/Board Member 63 21-09-01
More insiders
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.
More about the company